Given Imaging has reported revenues of $44.8m for the second quarter ended 30 June 2011, a 6.3% increase from $42.1m in the second quarter of 2010.
Revenues in the Americas region increased by 4% to $26.9m in the second quarter of 2011 from $25.9m in the same period last year.
Revenues in the EMEA region were $11.8m compared to $11.6m in the same period last year.
APAC revenues increased by 30% to $6m compared to $4.6m in the same period in 2010.
Worldwide PillCam SB sales amounted to 58,700 capsules in the second quarter of 2011, compared to 59,900 capsules in the same period last year.
Non-GAAP operating profit was $4.8m, compared to $7.2m during the same period in the prior year.
On a GAAP basis, net income for the second quarter of 2011 was $1.9m, compared to $2.2m in the same quarter of last year.
Given Imaging CEO and president Homi Shamir said they are pleased with another quarter of solid financial results, including the 4% increase in second quarter revenues in the Americas region.
"We are also encouraged by revenue growth of 14% in the EMEA region in the first six months of 2011, and confident that we will achieve our full year revenue goal for the region," Shamir said.
"On the development front, enrollment in the large multi-center PillCam COLON 2 pivotal trial which began in early June is proceeding on schedule and the majority of centers are actively enrolling patients."